Literature DB >> 19020907

LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity.

A Gorostidi1, J Ruiz-Martínez, A Lopez de Munain, A Alzualde, J F Martí Massó.   

Abstract

Mutations in LRRK2 gene are the most frequent cause of Parkinson's disease (PD) described, but their prevalence varies between populations. Patients, 418, with PD and 138 unrelated controls from the Basque Country were screened for LRRK2 G2019S and R1441G mutations. Of the patients, 3.82% were heterozygous carriers of G2019S and 13.15% of R1441G. G2019S frequency was higher in non-Basque population (6.0%), while R1441G was more common in Basque origin population (22.4%). Our conclusion is that both G2019S and R1441G mutations' frequency varies markedly between Basque and non-Basque origin population reinforcing the importance of ethnicity consideration when establishing mutation prevalence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020907     DOI: 10.1007/s10048-008-0162-0

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  11 in total

1.  G2019S LRRK2 mutation in French and North African families with Parkinson's disease.

Authors:  Suzanne Lesage; Pablo Ibanez; Ebba Lohmann; Pierre Pollak; François Tison; Myriem Tazir; Anne-Louise Leutenegger; Joao Guimaraes; Anne-Marie Bonnet; Yves Agid; Alexandra Dürr; Alexis Brice
Journal:  Ann Neurol       Date:  2005-11       Impact factor: 10.422

2.  Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques.

Authors:  Javier Simón-Sánchez; José-Félix Martí-Massó; José Vicente Sánchez-Mut; Coro Paisán-Ruiz; Angel Martínez-Gil; Javier Ruiz-Martínez; Amets Sáenz; Andrew B Singleton; Adolfo López de Munain; Jordi Pérez-Tur
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

3.  Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.

Authors:  María C González-Fernández; Elena Lezcano; Owen A Ross; Juan C Gómez-Esteban; Fernando Gómez-Busto; Fernando Velasco; Maite Alvarez-Alvarez; María B Rodríguez-Martínez; Roberto Ciordia; Juan J Zarranz; Matthew J Farrer; Ignacio F Mata; Marian M de Pancorbo
Journal:  Parkinsonism Relat Disord       Date:  2007-05-30       Impact factor: 4.891

4.  LRRK2 mutations are a common cause of Parkinson's disease in Spain.

Authors:  I F Mata; O A Ross; J Kachergus; C Huerta; R Ribacoba; G Moris; M Blazquez; L M Guisasola; C Salvador; C Martinez; M Farrer; V Alvarez
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

5.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.

Authors:  Alessio Di Fonzo; Christan F Rohé; Joaquim Ferreira; Hsin F Chien; Laura Vacca; Fabrizio Stocchi; Leonor Guedes; Edito Fabrizio; Mario Manfredi; Nicola Vanacore; Stefano Goldwurm; Guido Breedveld; Cristina Sampaio; Giuseppe Meco; Egberto Barbosa; Ben A Oostra; Vincenzo Bonifati
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

6.  LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.

Authors:  Carles Gaig; Mario Ezquerra; Maria Jose Marti; Esteban Muñoz; Francesc Valldeoriola; Eduardo Tolosa
Journal:  Arch Neurol       Date:  2006-03

7.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

8.  Is the G2019S LRRK2 mutation common in all southern European populations?

Authors:  Spiridon Papapetropoulos; Nikhil Adi; Lina Shehadeh; Nanette Bishopric; Carlos Singer; Andreas A Argyriou; Elizabeth Chroni
Journal:  J Clin Neurosci       Date:  2008-07-09       Impact factor: 1.961

9.  High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.

Authors:  Joaquim J Ferreira; Leonor Correia Guedes; Mário Miguel Rosa; Miguel Coelho; Marina van Doeselaar; Dorothea Schweiger; Alessio Di Fonzo; Ben A Oostra; Cristina Sampaio; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

Review 10.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01
View more
  22 in total

1.  Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.

Authors:  Byoung Dae Lee; Xiaojie Li; Ted M Dawson; Valina L Dawson
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Genetics of Parkinson's disease.

Authors:  Christine Klein; Ana Westenberger
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 4.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

5.  Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Authors:  Ilir Agalliu; Roberto A Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2019-07-26       Impact factor: 10.338

6.  Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.

Authors:  Xiaojie Li; Darren J Moore; Yulan Xiong; Ted M Dawson; Valina L Dawson
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

7.  The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Authors:  Ignacio F Mata; Marie Y Davis; Alexis N Lopez; Michael O Dorschner; Erica Martinez; Dora Yearout; Brenna A Cholerton; Shu-Ching Hu; Karen L Edwards; Thomas D Bird; Cyrus P Zabetian
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-04-25       Impact factor: 3.568

Review 8.  A Practical Approach to Early-Onset Parkinsonism.

Authors:  Giulietta M Riboldi; Emanuele Frattini; Edoardo Monfrini; Steven J Frucht; Alessio Di Fonzo
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.568

9.  Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Authors:  Chen Yao; William M Johnson; Yue Gao; Wen Wang; Jinwei Zhang; Maria Deak; Dario R Alessi; Xiongwei Zhu; John J Mieyal; Hanno Roder; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

10.  Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers.

Authors:  Ana Gorostidi; Alberto Bergareche; Javier Ruiz-Martínez; José F Martí-Massó; María Cruz; Shiji Varghese; Mohamed M Qureshi; Fatimah Alzahmi; Abdulmonem Al-Hayani; Adolfo López de Munáin; Omar M A El-Agnaf
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.